Login / Signup

Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.

Phillippe Gabriel StegDeepak L BhattStefan K JamesOliver DarlingtonLouise HoskinTabassome SimonKim M FoxLawrence A LeiterShamir R MehtaRobert A HarringtonAnders HimmelmannWilhelm RidderstråleMarielle AnderssonHéctor BuenoLeonardo De LucaAmarjeet TankCarl MellströmPhil McEwan
Published in: European heart journal. Cardiovascular pharmacotherapy (2022)
Based on THEMIS results, ticagrelor plus aspirin compared with aspirin alone may be cost-effective in some European countries in patients with T2DM and CAD and no prior myocardial infarction (MI) or stroke. Additionally, ticagrelor is likely to be cost-effective across European countries in patients with a history of PCI.
Keyphrases